These results indicate that therapeutic management of patients with high-risk MDS, especially those with high bone marrow levels of sIL-6R, through intervention via the IL-6 signaling pathway, such as using tocilizumab, could be beneficial by reducing the progression to AML. Here, IL6R is linked to myelodysplastic syndrome.